# Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

> **NCT05982834** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 43 (estimated)

## Conditions studied

- HER2-positive Gastric Cancer
- Immunotherapy

## Interventions

- **DRUG:** Disitamab Vedotin combined with fruquintinib and Tislelizumab

## Key facts

- **NCT ID:** NCT05982834
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-09
- **Primary completion:** 2025-05
- **Final completion:** 2025-12
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05982834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05982834, "Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05982834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*